Ftse Mib
38.456,17
0,09%
DAX
22.425,93
0,73%
S&P 500
5.983,25
-0,50%
NASDAQ
19.286,92
-1,21%
Bitcoin
93.059,97
-3,34%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Adicet Bio Inc (ACET) Adicet Bio Inc (ACET) Notizie

ACET

Adicet Bio (ACET)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACET
DataOraFonteTitoloSimboloCompagnia
05/02/202513:10Business WireAdicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal InvolvementNASDAQ:ACETAdicet Bio Inc
05/02/202513:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACETAdicet Bio Inc
04/02/202522:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
01/02/202500:06Business WireAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACETAdicet Bio Inc
29/01/202513:00Business WireAdicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech ConferenceNASDAQ:ACETAdicet Bio Inc
23/01/202522:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
08/01/202522:10Business WireAdicet Bio Provides Corporate Update and Highlights Expected 2025 MilestonesNASDAQ:ACETAdicet Bio Inc
31/12/202422:48Business WireAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACETAdicet Bio Inc
19/12/202413:00Business WireAdicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell CarcinomaNASDAQ:ACETAdicet Bio Inc
18/12/202413:00Business WireAdicet Bio Appoints Julie Maltzman, M.D. as Chief Medical OfficerNASDAQ:ACETAdicet Bio Inc
18/11/202422:00Business WireAdicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell CarcinomaNASDAQ:ACETAdicet Bio Inc
18/11/202413:00Business WireAdicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune DiseasesNASDAQ:ACETAdicet Bio Inc
16/11/202415:00Business WireAdicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024NASDAQ:ACETAdicet Bio Inc
14/11/202422:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ACETAdicet Bio Inc
06/11/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACETAdicet Bio Inc
06/11/202422:00Business WireAdicet Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ACETAdicet Bio Inc
05/11/202413:00Business WireAdicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024NASDAQ:ACETAdicet Bio Inc
01/11/202412:00Business WireAdicet Bio to Participate in Upcoming Investor ConferencesNASDAQ:ACETAdicet Bio Inc
16/10/202413:00Business WireAdicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person SyndromeNASDAQ:ACETAdicet Bio Inc
30/09/202422:30Business WireAdicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer ConferenceNASDAQ:ACETAdicet Bio Inc
30/09/202413:00Business WireAdicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune DiseasesNASDAQ:ACETAdicet Bio Inc
19/09/202413:00Business WireADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid TissueNASDAQ:ACETAdicet Bio Inc
27/08/202422:00Business WireAdicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ACETAdicet Bio Inc
19/08/202413:00Business WireAdicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of DirectorsNASDAQ:ACETAdicet Bio Inc
13/08/202413:00Business WireAdicet Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ACETAdicet Bio Inc
08/07/202413:00Business WireAdicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell CarcinomaNASDAQ:ACETAdicet Bio Inc
24/06/202413:00Business WireAdicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell CarcinomaNASDAQ:ACETAdicet Bio Inc
05/06/202413:00Business WireAdicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus NephritisNASDAQ:ACETAdicet Bio Inc
29/05/202413:00Business WireAdicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare ConferenceNASDAQ:ACETAdicet Bio Inc
14/05/202422:01Business WireAdicet Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ACETAdicet Bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACET

La tua Cronologia

BIT
SPM
Saipem
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
G
Generali
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci